about
Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptaseDetermination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies.Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy.Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy.C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s.The Global HIV Drug Resistance Surveillance Program: a partnership between WHO and IAS. International AIDS Society.Scott Hammer--integrating research with politics, public policy, and international collaborations. Interviewed by Marilynn Larkin.
P50
Q26765043-BCB12E97-5E6F-46C0-ACE4-D01BA6EEEB4AQ28481004-94242D36-DE23-4209-8FAD-0FA1848E3F8BQ31150412-B0AA528A-8ABB-47B4-B4EA-3905C5D00FE8Q33592278-D00649BF-BD9F-4E05-B108-3A9BC5216185Q33649563-5CC2C206-90A4-44BB-995F-022D49616ECBQ33739249-689705E3-7407-4988-A018-9952D41F4AD2Q35728947-8A5B696C-18E0-4CA2-B44B-3DD58938B01EQ36100031-9E5ED922-EDBB-4B80-AAC5-3DA46ABD0B5BQ37021742-eec8adb7-4fd9-aa9e-0037-6aeebcb4081cQ43000589-7AD5A613-3B00-4472-AFF4-11487F1846DFQ43833652-FF52B42F-9B23-4037-A171-EB6300876C8FQ44286350-49788663-25EA-446B-BF60-8C0BBE392F5FQ48685640-91C29A31-41CB-4763-9677-476024E034B6
P50
description
medical researcher
@en
name
Scott M. Hammer
@en
Scott M. Hammer
@nl
type
label
Scott M. Hammer
@en
Scott M. Hammer
@nl
altLabel
S. M. Hammer
@en
SM Hammer
@en
Scott Hammer
@en
prefLabel
Scott M. Hammer
@en
Scott M. Hammer
@nl